{"nctId":"NCT00132678","briefTitle":"A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes","startDateStruct":{"date":"2005-02"},"conditions":["Bipolar Disorder"],"count":559,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Risperdal Consta"]},{"label":"002","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Risperdal Consta","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of bipolar 1 disorder, currently experiencing a mixed or manic episode or stable\n* Two or more bipolar mood episodes in the last 2 years excluding current episode\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* History of \\> than 4 mood episodes a year during the last two years\n* patients experiencing a depressive episode\n* History of antisocial or borderline personality illness\n* Has unstable or serious general medical illness\n* Has received medications disallowed by study criteria.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Had a Mood Relapse.","description":"Mood Relapse was defined as:\n\nThe subject met DSM-IV criteria for a manic, hypomanic, mixed, or depressive episode; or, the subject needed treatment intervention with any mood stabilizer, antipsychotic medication (other than study drug), benzodiazepine (beyond the dosage allowed), or antidepressant medication; or the subject required hospitalization for any bipolar mood episode; or the subject had a YMRS or MADRS score \\>12 or a CGI-S score \\>4; or a dose increase, or supplementation with oral risperidone or another antipsychotic or mood stabilizer, was needed in the opinion of the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Young Mania Rating Scale (YMRS) Scores.","description":"Measure of mania; score range 0 to 60 (lower score = less severity)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"7.34"},{"groupId":"OG001","value":"9.1","spread":"10.78"}]}]}]},{"type":"SECONDARY","title":"Change in Montgomery-Ã…sberg Depression Rating Scale (MADRS)","description":"Measure of depression; score range 0 to 60 (lower score = less severity)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"6.66"},{"groupId":"OG001","value":"4.9","spread":"8.09"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":154},"commonTop":["Insomnia","Headache","Agitation","Sommolence","Anxiety"]}}}